Mirum Pharmaceuticals Inc（MIRM）財務資料MIRMMirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. (MIRM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Livmarli, accounting for 73.0% of total sales, equivalent to $128.72M. Another important revenue stream is Bile Acid Medicines. Understanding this composition is critical for investors evaluating how MIRM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Mirum Pharmaceuticals, Inc. maintains a gross margin of 82.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -14.81%, while the net margin is -38.14%. These profitability ratios, combined with a Return on Equity (ROE) of -702.97%, provide a clear picture of how effectively MIRM converts its operational activities into shareholder value.

In the context of the broader market, MIRM competes directly with industry leaders such as ERAS and TVTX. With a market capitalization of $6.53B, it holds a significant position in the sector. When comparing efficiency, MIRM's gross margin of 82.78% stands against ERAS's N/A and TVTX's 96.45%. Such benchmarking helps identify whether Mirum Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Mirum reported Q2 2026 revenue of $176 million, a 37.5% year-over-year increase, but a GAAP EPS of -$1.06, missing expectations by $0.32.